| Ident. | Authors (with country if any) | Title |
|---|
| 000360 |
Alexander Schacht [Allemagne] ; Philip Gorwood [France] ; Philip Boyce [Australie] ; Ayal Schaffer [Canada] ; Hernan Picard [Royaume-Uni] | Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials |
| 000C27 |
Thibault Renoir [Australie] ; Terence Yc Pang [Australie] ; Michelle S. Zajac [Australie] ; Grace Chan [Australie] ; XIN DU [Australie] ; Leah Leang [Australie] ; Caroline Chevarin [France] ; Laurence Lanfumey [France] ; Anthony J. Hannan [Australie] | Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise |
| 001376 |
Trevor R. Norman [Australie] ; Ingrid Cranston [Australie] ; Jeremy A. Irons [Australie] ; Cecilia Gabriel [France] ; Anne Dekeyne [France] ; Mark J. Millan [France] ; Elisabeth Mocaer [France] | Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006 |
| 001D31 |
H. Ascher-Svanum [États-Unis] ; X. Peng [États-Unis] ; W. Montgomery [Australie] ; D. E. Faries [États-Unis] ; A. H. Lawson [États-Unis] ; M. M. Witte [États-Unis] ; D. Novick [Royaume-Uni] ; N. Jemiai [Royaume-Uni] ; E. Perrin [France] ; D. P. Mcdonnell [Royaume-Uni] | Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia |
| 002D74 |
Rajiv Tandon [États-Unis] ; R. H. Belmaker [Israël] ; Wagner F. Gattaz [Brésil] ; Juan J. Jr Lopez-Ibor [Espagne] ; Ahmed Okasha [Égypte] ; Bruce Singh [Australie] ; Dan J. Stein [Afrique du Sud] ; Jean-Pierre Ojie [France] ; W. Wolfang Fleischhacker [Autriche] ; Hans-Juergen Moeller [Allemagne] | World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia |
| 003586 |
Bernhard J. Steinhoff [Allemagne] ; Ernest R. Somerville [Australie] ; Wim Van Paesschen [Belgique] ; Philippe Ryvlin [France] ; Isabelle Schelstraete [Belgique] | The SKATETM study : An open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy |
| 003680 |
Nicolas Atrux-Tallau [France] ; Fabrice Pirot [France] ; Francoise Falson [France] ; Michael S. Roberts [Australie] ; Howard I. Maibach [États-Unis] | Qualitative and quantitative comparison of heat separated epidermis and dermatomed skin in percutaneous absorption studies |
| 003813 |
J. Espallergues [France] ; P. Lapalud [France] ; A. Christopoulos [Australie] ; V. A. Aviani [Australie] ; P. M. Sexton [Australie] ; A. Vamvakides [Grèce] ; T. Maurice [France] | Involvement of the sigma1 (σ1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41 |
| 003814 |
J. Espallergues [France] ; P. Lapalud [France] ; A. Christopoulos [Australie] ; V. A. Aviani [Australie] ; P. M. Sexton [Australie] ; A. Vamvakides [Grèce] ; T. Maurice [France] | Involvement of the sigma1 (σ1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41 |
| 003902 |
A. J. Lawrence [Australie] ; A. Newman-Tancredi [Australie] ; M-B Assie [Australie] ; J-C Martel [Australie] ; C. Cosi [France] ; L. Bruins Slot [France] ; C. Palmier [France] ; I. Rauly-Lestienne [France] ; F. Colpaert [France] ; B. Vacher [France] ; D. Cussac [France] | F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (I) in vitro receptor affinity and efficacy profile |
| 003903 |
A. J. Lawrence [Australie] ; R. Depoortere [Australie] ; A. L. Auclair [Australie] ; L. Bardin [Australie] ; L. Bruins Slot [Australie] ; M. S. Kleven [Australie, France] ; F. Colpaert [France] ; B. Vacher [France] ; A. Newman-Tancredi [Australie] | F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (III) activity in models of cognition and negative symptoms |
| 003904 |
A. J. Lawrence [Australie] ; R. Depoortere [Australie] ; L. Bardin [Australie] ; A. L. Auclair [Australie] ; M. S. Kleven [Australie, France] ; E. Prinssen [Australie] ; F. Colpaert [France] ; B. Vacher [France] ; A. Newman-Tancredi [Australie] | F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) activity in models of positive symptoms of schizophrenia |
| 004635 |
Howard Feldman [Canada] ; Serge Gauthier [Canada] ; Jane Hecker [Australie] ; Bruno Vellas [France] ; YIKANG XU [États-Unis] ; John R. Ieni [États-Unis] ; Elias M. Schwam [États-Unis] | Efficacy and safety of donepezil in patients with more severe Alzheimer's disease : a subgroup analysis from a randomized, placebo-controlled trial |
| 004734 |
G. S. Malhi [Australie] ; M. Berk [Australie] ; M. Bourin [France] ; B. Ivanovski [Australie] ; S. Dodd [Australie] ; J. Lagopoulos [Australie] ; P. B. Mitchell [Australie] | Atypical mood stabilizers: a 'typical' role for atypical antipsychotics |
| 004909 |
Pascal Kintz [France] ; Marion Villain [France] ; Bertrand Ludes [France] | Testing for zolpidem in oral fluid by liquid chromatography-tandem mass spectrometry |
| 004C90 |
S. A. Montgomery [Royaume-Uni] ; S. H. Kennedy [Canada] ; G. D. Burrows [Australie] ; M. Lejoyeux [France] ; I. Hindmarch [Royaume-Uni] | Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study |
| 004D31 |
C. Gury [France] ; D. Ames [Australie] ; J. Camm [Royaume-Uni] ; P. Cook [Canada] ; P. Falkai [Allemagne] ; R. Hurley [Australie] ; G. Johnson [Australie] ; R. Piepho [États-Unis] ; V. Vieweg [États-Unis] | Comment minimiser les risques associés à un allongement significatif de l'intervalle QTc chez les personnes souffrant de schizophrénie. Recommandations consensuelles du Cardiac safety in schizophrenia group |
| 005130 |
D. Ames [Australie] ; J. Camm [Royaume-Uni] ; P. Cook [Canada] ; P. Falkai [Allemagne] ; C. Gury [France] ; R. Hurley [Australie] ; G. Johnson [Australie] ; R. Piepho [États-Unis] ; V. Vieweg [États-Unis] | Comment minimiser les risques associés à un allongement significatif de l'intervalle QTc chez les personnes souffrant de schizophrénie. Recommandations consensuelles du Cardiac Safety in Schizophrenia Group (CSISG) |
| 005414 |
S. Gauthier [Canada] ; H. Feldman [Canada] ; J. Hecker [Australie] ; B. Vellas [France] ; B. Emir [États-Unis] ; P. Subbiah [États-Unis] | Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease |
| 005453 |
Serge Gauthier [Canada] ; Howard Feldman [Canada] ; Jane Hecker [Australie] ; Bruno Vellas [France] ; David Ames [Australie] ; Ponni Subbiah [États-Unis] ; Edward Whalen [États-Unis] ; Birol Emir [États-Unis] | Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease |
| 005581 |
S. Kasper [Australie] ; D. Sechter [Australie] | Observances et posologies |
| 005993 |
R. Rezaie [France] ; B. Joseph [France] ; J. B. Bremner [Australie] ; P. Delagrange [France] ; C. Kopp [France] ; R. Misslin [France] ; B. Pfeiffer [France] ; P. Renard [France] ; G. Guillaumet [France] | 5-substituted 3,4-dihydro-3-amino-2H-1-benzopyran derivatives: synthesis and interaction with serotoninergic receptors |
| 005F23 |
C. Katona [Royaume-Uni] ; E. Bercoff [France] ; E. Chiu [Australie] ; P. Tack [Belgique] ; M. Versiani [Brésil] ; H. Woelk [Allemagne] | Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial |
| 006667 |
J. C. Speller [Royaume-Uni] ; T. R. E. Barnes [Royaume-Uni] ; D. A. Curson [Royaume-Uni] ; C. Pantelis [Australie] ; J. L. Alberts [France] | One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms : Amisulpride v. haloperidol |
